-

Phibro Issues Inaugural Environmental, Social and Governance Report

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC), a diversified global developer, manufacturer, and supplier of a broad range of animal health and mineral nutrition products for livestock, published its inaugural Environmental, Social and Governance (ESG) Report (the “Report”). The Report establishes Phibro’s baseline on certain key performance indicators as of December 31, 2021, by providing disclosures containing relevant, industry-specific data and information aligned with the Sustainability Accounting Standards Board (SASB) framework, along with select disclosures aligned with the Global Reporting Initiative (GRI) framework. In addition, the Report captures the myriad ways Phibro empowers its people, protects the environment, acts with integrity, and engages with the communities in which it operates globally.

“This first ESG Report demonstrates the commitment of the entire Phibro team. Throughout history, raising healthy animals has been foundational to a healthy, affordable food supply and ultimately, to our survival as a civilization. As the world population grows and challenges mount, we at Phibro have a responsibility to meet the demand for safe, affordable protein and do it more sustainably,” commented Jack Bendheim, Phibro’s Chairman, President & Chief Executive Officer.

Damian Finio, Phibro’s CFO and Chairman of Phibro’s ESG Council, stated, “At Phibro, we are serious about ESG because the principles align with our values and how we have done business for years. Speaking on behalf of our employees around the world, we are very excited to be sharing our story publicly for the first time.”

Phibro intends to review progress against the metrics contained in the Report regularly, and to publish revisions periodically.

To read Phibro Animal Health Corporation’s inaugural ESG Report, please visit https://www.pahc.com/responsibility

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a diversified global developer, manufacturer, and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources. For further information, please visit www.pahc.com.

Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties, including risks relating to the potential FDA withdrawal of approval of our Mecadox (carbadox) product. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.

Contacts

Damian Finio
Chief Financial Officer, Phibro Animal Health Corporation
+1 201-329-7300
investor.relations@pahc.com

Phibro Animal Health Corporation

NASDAQ:PAHC

Release Versions

Contacts

Damian Finio
Chief Financial Officer, Phibro Animal Health Corporation
+1 201-329-7300
investor.relations@pahc.com

More News From Phibro Animal Health Corporation

Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2025 and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended September 30, 2025 (compared to the three months ended September 30, 2024) Net sales of $363.9 million, an increase of $103.5 million, or 40% Net income of $26.5 million, an increase of $19.6 million Di...

Phibro Animal Health Corporation Declares Quarterly Dividend

TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner w...

Phibro Animal Health Corporation Announces National Launch of Restoris™ Piezoelectric Dental Gel for Dogs

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual mechanism of action to restore oral health at its foundation. The launch of Re...
Back to Newsroom